{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CONTROL+Group&page=38",
    "query": {
      "intervention": "CONTROL Group",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 33487,
    "total_pages": 3349,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CONTROL+Group&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CONTROL+Group&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T17:24:15.436Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03727074",
      "title": "Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Actinic Keratosis (AK)"
      ],
      "interventions": [
        {
          "name": "5-FU Cream",
          "type": "DRUG"
        },
        {
          "name": "Efudex®",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sol-Gel Technologies, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 462,
      "start_date": "2018-12-21",
      "completion_date": "2019-12-19",
      "has_results": false,
      "last_update_posted_date": "2020-03-18",
      "last_synced_at": "2026-10-25T17:24:15.436Z",
      "location_count": 1,
      "location_summary": "Cerritos, California",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03727074"
    },
    {
      "nct_id": "NCT01679990",
      "title": "Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Intermittent Claudication",
        "Peripheral Artery Disease"
      ],
      "interventions": [
        {
          "name": "PLX-PAD Low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PLX-PAD high doses",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Double Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "high dose +Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pluristem Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "45 Years to 85 Years"
      },
      "enrollment_count": 180,
      "start_date": "2012-11-05",
      "completion_date": "2019-02-09",
      "has_results": false,
      "last_update_posted_date": "2019-02-12",
      "last_synced_at": "2026-10-25T17:24:15.436Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Clearwater, Florida • Gainesville, Florida + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Pinellas Park",
          "state": "Florida"
        },
        {
          "city": "Evans",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01679990"
    },
    {
      "nct_id": "NCT01074190",
      "title": "The Effect of Neuraxial Analgesia on Maternal Breastfeeding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain",
        "Breastfeeding"
      ],
      "interventions": [
        {
          "name": "Group 1",
          "type": "DRUG"
        },
        {
          "name": "Group 2",
          "type": "DRUG"
        },
        {
          "name": "Group 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 345,
      "start_date": "2010-01",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-05",
      "last_synced_at": "2026-10-25T17:24:15.436Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01074190"
    },
    {
      "nct_id": "NCT03947697",
      "title": "Improving Glycemic Control With Electrical Stimulation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Overweight",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Neuromuscular Electrical Stimulation (Sensory)",
          "type": "DEVICE"
        },
        {
          "name": "Neuromuscular Electrical Stimulation",
          "type": "DEVICE"
        },
        {
          "name": "Resistance Training",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Texas, El Paso",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2022-08-09",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-25T17:24:15.436Z",
      "location_count": 1,
      "location_summary": "El Paso, Texas",
      "locations": [
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03947697"
    },
    {
      "nct_id": "NCT04667182",
      "title": "A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type 1 Diabetes",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Meal-Tagging App and Web-based Portal:",
          "type": "OTHER"
        },
        {
          "name": "Fitness Tracker",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "25 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-01-25",
      "completion_date": "2021-12-06",
      "has_results": false,
      "last_update_posted_date": "2021-09-17",
      "last_synced_at": "2026-10-25T17:24:15.436Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04667182"
    },
    {
      "nct_id": "NCT01342224",
      "title": "Immunochemoradiotherapy in Patients With Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "tadalafil and vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2011-01",
      "completion_date": "2018-04",
      "has_results": false,
      "last_update_posted_date": "2018-04-12",
      "last_synced_at": "2026-10-25T17:24:15.436Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01342224"
    },
    {
      "nct_id": "NCT01728324",
      "title": "Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "BI 207127-placebo: 8-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin: 24-week treatment",
          "type": "DRUG"
        },
        {
          "name": "BI 207127: 24-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Faldaprevir: 24-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin-placebo: 8-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Faldaprevir-placebo: 8-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Faldaprevir: 16-week treatment",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin: 16-week treatment",
          "type": "DRUG"
        },
        {
          "name": "RBV: 24-week treatment",
          "type": "DRUG"
        },
        {
          "name": "BI 207127: 16-week treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 496,
      "start_date": "2012-11",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-02-12",
      "last_synced_at": "2026-10-25T17:24:15.436Z",
      "location_count": 31,
      "location_summary": "North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more",
      "locations": [
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01728324"
    },
    {
      "nct_id": "NCT03417479",
      "title": "Gabapentin Premedication for ACL Reconstruction: RCT",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Anterior Cruciate Ligament (ACL) Reconstruction"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Children's Healthcare of Atlanta",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "12 Years to 18 Years"
      },
      "enrollment_count": 57,
      "start_date": "2015-10-09",
      "completion_date": "2018-10-23",
      "has_results": false,
      "last_update_posted_date": "2021-12-08",
      "last_synced_at": "2026-10-25T17:24:15.436Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03417479"
    },
    {
      "nct_id": "NCT01107496",
      "title": "Evaluation of Immediate-Release Viloxazine in Adults With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "IR Viloxazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 52,
      "start_date": "2010-06",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-10-25T17:24:15.436Z",
      "location_count": 4,
      "location_summary": "Bradenton, Florida • Libertyville, Illinois • Owensboro, Kentucky + 1 more",
      "locations": [
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Libertyville",
          "state": "Illinois"
        },
        {
          "city": "Owensboro",
          "state": "Kentucky"
        },
        {
          "city": "Herndon",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01107496"
    },
    {
      "nct_id": "NCT07362862",
      "title": "MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sepsis",
        "Critical Illness",
        "ICU-acquired Muscle Weakness",
        "ICU-acquired Weakness",
        "ICUAW",
        "Sarcopenia",
        "Secondary Sarcopenia"
      ],
      "interventions": [
        {
          "name": "Electrical Muscle Stimulation System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Health Discovery Labs",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-05-05",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-25T17:24:15.436Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • Austin, Texas",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07362862"
    }
  ]
}